Breast Cancer

Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.

Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.

Jane L. Meisel, MD, discusses managing toxicities associated with ado-trastuzumab emtansine in patients with HER2-positive breast cancer.

Chemoimmunotherapy has become the standard of care for the frontline treatment of patients with PD-L1–positive, locally advanced or metastatic triple-negative breast cancer. However, understanding which patients will derive the most benefit from the approach is in need of further exploration

Optimal patient selection and duration of therapy are the 2 biggest areas to tackle regarding CDK4/6 inhibition in the adjuvant setting of estrogen receptor–positive breast cancer.

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.

Although endocrine therapies have revolutionized the treatment of breast cancers driven by the estrogen receptor, the development of resistance remains a major challenge that limits long-term remission with currently available drugs.

The Marshalls go beyond the pages of their new memoir, Off Our Chests: A Candid Tour Through the World of Cancer, to discuss how Liza's diagnosis of triple-negative breast cancer changed their lives and the key messages they hope readers will take from their book.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

A new drug application has been submitted to the FDA and the China National Medical Products Administration for the use of plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

A biologics license application has been submitted to the FDA for the approval of F-627 as a treatment option for patients with breast cancer who have chemotherapy-induced neutropenia.

Kevin Kalinsky, MD, MS, discusses the potential role of ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

Julia R. White, MD, discusses research with regional nodal irradiation in node-positive breast cancer.

The FDA has issued a complete response letter to Merck stating that regulatory decision for the supplemental biologics license application seeking approval for pembrolizumab for use in patients with high-risk, early-stage triple-negative breast cancer plus chemotherapy as neoadjuvant treatment, then continuing as a single agent as adjuvant treatment following surgery, should be deferred.

The European Medicines Agency has validated a Marketing Authorization application for sacituzumab govitecan-hziy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who had previously received at least 2 therapies, including at least 1 therapy for locally advanced or metastatic disease.

Palbociclib in combination with endocrine therapy resulted in improved survival outcomes in a real-world population of patients with hormone receptor–positive, HER2-negative, metastatic breast cancer vs letrozole alone in the first-line setting.

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Patrick Borgen, MD, discusses common symptoms of breast cancer in male patients.

Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.

Although Ki-67 is a commonly used measure of cellular proliferation in breast cancer tissue, its utility as a biomarker for helping to guide therapy decisions has been clouded by technical and clinical questions.

Adam M. Brufsky, MD, PhD, discusses treatment options for male patients with breast cancer.

Patrick I. Borgen, MD, discusses male breast cancer in further detail, how he approaches treatment in his male patients with the disease, and what can be done to remove the stigma that men often feel with a breast cancer diagnosis.